$EQ
Equillium, Inc.

2019 Q2 Form 10-Q Financial Statement

#000156459019018839 Filed on May 13, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2019 Q1 2018 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.190M $2.590M
YoY Change
% of Gross Profit
Research & Development $4.250M $3.759M $663.0K
YoY Change 687.04% 466.97%
% of Gross Profit
Depreciation & Amortization $0.00 $10.00K
YoY Change
% of Gross Profit
Operating Expenses $6.439M $6.348M $1.037M
YoY Change 472.36% 512.15% -1643.27%
Operating Profit -$6.439M -$6.348M -$1.037M
YoY Change 472.36% 512.15%
Interest Expense $380.0K $400.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net $370.0K $398.0K -$540.0K
YoY Change -157.81% -173.7%
Pretax Income -$6.070M -$5.950M
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$6.069M -$5.950M -$1.577M
YoY Change 243.85% 277.3% 2246.9%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$349.3K -$342.3K
COMMON SHARES
Basic Shares Outstanding 17.38M 17.38M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2019 Q1 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $56.94M $61.61M
YoY Change 762.79%
Cash & Equivalents $22.66M $21.39M $6.209M
Short-Term Investments $34.28M $40.21M
Other Short-Term Assets $900.0K $1.000M
YoY Change 800.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $57.80M $62.63M
YoY Change 762.63%
LONG-TERM ASSETS
Property, Plant & Equipment $77.00K $83.00K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $15.00K $15.00K
YoY Change
Total Long-Term Assets $92.00K $98.00K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $57.80M $62.63M
Total Long-Term Assets $92.00K $98.00K
Total Assets $57.89M $62.73M
YoY Change 764.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.974M $1.588M
YoY Change 558.0%
Accrued Expenses $1.688M $1.464M
YoY Change 181.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.662M $3.052M
YoY Change 306.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $200.0K $200.0K
YoY Change -77.78%
Total Long-Term Liabilities $163.0K $181.0K
YoY Change -98.57%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.662M $3.052M
Total Long-Term Liabilities $163.0K $181.0K
Total Liabilities $3.825M $3.233M
YoY Change -68.9%
SHAREHOLDERS EQUITY
Retained Earnings -$27.53M -$21.46M
YoY Change
Common Stock $81.51M $80.91M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $54.06M $59.49M -$3.829M
YoY Change
Total Liabilities & Shareholders Equity $57.89M $62.73M
YoY Change 764.0%

Cashflow Statement

Concept 2019 Q2 2019 Q1 2018 Q1
OPERATING ACTIVITIES
Net Income -$6.069M -$5.950M -$1.577M
YoY Change 243.85% 277.3% 2246.9%
Depreciation, Depletion And Amortization $0.00 $10.00K
YoY Change
Cash From Operating Activities -$4.760M -$4.464M -$889.0K
YoY Change 131.07% 402.14%
INVESTING ACTIVITIES
Capital Expenditures -$50.00K $11.00K $5.000K
YoY Change 150.0% 120.0%
Acquisitions
YoY Change
Other Investing Activities $6.090M -$2.640M
YoY Change
Cash From Investing Activities $6.040M -$2.651M -$5.000K
YoY Change -30300.0% 52920.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -4.760M -4.464M -889.0K
Cash From Investing Activities 6.040M -2.651M -5.000K
Cash From Financing Activities 0.000
Net Change In Cash 1.280M -7.115M -894.0K
YoY Change -366.67% 695.86%
FREE CASH FLOW
Cash From Operating Activities -$4.760M -$4.464M -$889.0K
Capital Expenditures -$50.00K $11.00K $5.000K
Free Cash Flow -$4.710M -$4.475M -$894.0K
YoY Change 130.88% 400.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
40213000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
37405000
CY2019Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1022000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1186000
CY2019Q1 us-gaap Assets Current
AssetsCurrent
62629000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
67099000
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
83000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
64000
CY2019Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15000
CY2019Q1 us-gaap Assets
Assets
62727000
CY2018Q4 us-gaap Assets
Assets
67163000
CY2019Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1588000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1119000
CY2019Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1464000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
909000
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3052000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2028000
CY2019Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
181000
CY2018Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
200000
CY2019Q1 us-gaap Liabilities
Liabilities
3233000
CY2018Q4 us-gaap Liabilities
Liabilities
2228000
CY2019Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
1000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2019Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
80906000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
80441000
CY2019Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
49000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5000
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-21462000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
59494000
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
62727000
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17376236
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17376236
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3759000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2589000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
374000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
6348000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
1037000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6348000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1037000
CY2018Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
489000
CY2019Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
398000
CY2018Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
5000
CY2019Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2019Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2019Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
17376236
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21394000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28508000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-15512000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
64935000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
67163000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17376236
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17376236
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
663000
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
44000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
455000
CY2019Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4000
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
555000
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
128000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4464000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-889000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11000
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5000
CY2019Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
14215000
CY2019Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
11575000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2651000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7115000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-894000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28509000
CY2018Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
446000
CY2018Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-489000
CY2019Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
124000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-149000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-18000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17376236
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10708074
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-2252000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
-3829000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
19000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
446000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-5950000
CY2018Q1 us-gaap Profit Loss
ProfitLoss
-1577000
CY2018Q1 eq Change In Fair Value Adjustment Of Anti Dilution Right
ChangeInFairValueAdjustmentOfAntiDilutionRight
56000
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
398000
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-540000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-5950000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1577000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
44000
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5906000
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1577000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7103000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
21394000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6209000
CY2019Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
13000
CY2018Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
6000
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1150483
CY2019Q1 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
40213000
CY2018Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
37405000
CY2019Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s condensed consolidated financial statements requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the condensed consolidated financial statements and accompanying notes. Significant estimates in the Company&#8217;s condensed consolidated financial statements relate to clinical trial accruals and the valuation of equity awards. Management evaluates its estimates on an ongoing basis. Although estimates are based on the Company&#8217;s historical experience, knowledge of current events, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. </p>
CY2019Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2017-03-16
CY2019Q1 dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Delaware
CY2019Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
61600000
CY2019Q1 us-gaap Share Price
SharePrice
5.65
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
446000
CY2019Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
40164000
CY2019Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2019Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
50000
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
37400000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5000
CY2019Q1 us-gaap Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities
0
CY2019Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
315000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
560000
CY2019Q1 eq Accrued Clinical Studies
AccruedClinicalStudies
866000
CY2018Q4 eq Accrued Clinical Studies
AccruedClinicalStudies
245000
CY2019Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
131000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
96000
CY2019Q1 eq Accrued Preclinical Studies
AccruedPreclinicalStudies
152000
CY2018Q4 eq Accrued Preclinical Studies
AccruedPreclinicalStudies
8000
CY2017Q2 us-gaap Proceeds From Sale Of Available For Sale Securities Equity
ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
15000000
CY2019Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3169450
CY2018Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2126877
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0256
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9301
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M1D
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00

Files In Submission

Name View Source Status
0001564590-19-018839-index-headers.html Edgar Link pending
0001564590-19-018839-index.html Edgar Link pending
0001564590-19-018839.txt Edgar Link pending
0001564590-19-018839-xbrl.zip Edgar Link pending
eq-10q_20190331.htm Edgar Link pending
eq-20190331.xml Edgar Link completed
eq-20190331.xsd Edgar Link pending
eq-20190331_cal.xml Edgar Link unprocessable
eq-20190331_def.xml Edgar Link unprocessable
eq-20190331_lab.xml Edgar Link unprocessable
eq-20190331_pre.xml Edgar Link unprocessable
eq-ex311_8.htm Edgar Link pending
eq-ex312_6.htm Edgar Link pending
eq-ex321_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending